Phase 4Active, not recruitingINTERVENTIONAL
Effects of Long-Acting GLP-1 (Glucagon-like Peptide-1) or Dual Incretin (GLP-1 and GIP [Glucose-dependent Insulinotropic Peptide]) Modulation on Gastric Motor Functions
ClinicalTrials.gov · NCT06801015 · Registry updated: 2025-12-26
- Condition / research focus
- Obesity
- Sponsor
- Mayo Clinic
- Countries with listed sites
- United States
- Registry dates and results
- Start: 2025-10-01. Completion: 2028-03-31 (may be estimated). No results posted in this registry response.
Products and interventions (3)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
- Semaglutide (drug)
- Tirzepatide (drug)
- Placebo (drug)
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
- Mayo Clinic in RochesterRochester, Minnesota, United States